Colorectal CancerNCT01589900
Identification the Expression of Sox2 in Colorectal Cancer Tissues
An observational study of Colorectal Cancer, run by Sun Yat-sen University.
Trial summary
Sox2 has been studied in several types of human solid tumors. The investigators found that Sox2 had higher expression level in colorectal cancer and metastatic tissues than normal tissues. So the investigators assumed that whether Sox2 plays an important role in the progression and migration of colon cancer. Read more about this study
- Who is it for?
- Ages 24 to 79 years
- Conditions the study is for
- Colorectal Cancer
- How many people
- 136 participants
- Where
- No sites listed yet
- Study dates
- Jan 2005to Mar 2012
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 24 to 79 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: All rchived 136 tissues were obtained and pathologically confirmed from patients who underwent surgical resections between 2005 and 2006 at the Cancer Center of Sun Yat-sen University (Guangzhou, Guangdong, P. R. China)). The patients from whom the samples were derived underwent curative resection between 2005 and 2006. Tumor differentiation was characterized according to WHO classification, while the surgical pathologic stage was analyzed according to the TNM classification system of the International Union against Cancer. All samples were anonymously coded in accordance with local ethical guidelines.
Who may be able to join
- Clinical diagnosis of colorectal cancer
Who cannot join
- Clinical diagnosis characteristics not exactly described in the patients information
About this study
Official title: The Role of Sox2 in Tumor Genesis and Migration in Colorectal Cancer
Sox2 has been studied in several types of human solid tumors. The investigators found that Sox2 had higher expression level in colorectal cancer and metastatic tissues than normal tissues. So the investigators assumed that whether Sox2 plays an important role in the progression and migration of colon cancer.
Read the detailed description
In our study, we examined Sox2 expression in archived human colon cancer tissues and found that its Sox2 expression correlates with reduced patient survival, increased tumor grade and metastasis probability.
- Conditions
- Colorectal Cancer
- Keywords
- colorectal cancer, invasion, metastasis, IHC
- Medical subject headings
- Colorectal Neoplasms, Neoplasm Metastasis
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 May 2012 (estimated)
- Study startJan 2005
- Primary completionDec 2006
- Study completionMar 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Colorectal CancerStudies of the same condition, open and under way.
- More trials run by Sun Yat-sen UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 136 participants (actual)
Sponsor and investigators
- Lead sponsor
- Sun Yat-sen University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Lixiao Xu, Sun Yat-sen University
- Investigators
- Yan Zhang, M.D.Ph.D, Principal investigator, Laboratory of Cancer and Stem Cell Biology School of Life Sciences Sun Yat-sen University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01589900
- Sponsor's protocol ID
- SYSU
- Status last verified
- May 2012
- First submitted
- 30 Apr 2012
- Last updated
- 3 May 2012
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 3 May 2012. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Role of Sox2 in Tumor Genesis and Migration in Colorectal Cancer
- ClinicalTrials.gov ID
- NCT01589900
- Acronym / sponsor ID
- SYSU
- Conditions
- Colorectal Cancer
- Keywords
- colorectal cancer, invasion, metastasis, IHC
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 136 participants (actual)
- Lead sponsor
- Sun Yat-sen UniversityUniversity, hospital or other
- Study start
- Jan 2005
- Primary completion
- Dec 2006 (actual)
- Study completion
- Mar 2012 (actual)
- First posted
- 2 May 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Sox2 has been studied in several types of human solid tumors. The investigators found that Sox2 had higher expression level in colorectal cancer and metastatic tissues than normal tissues. So the investigators assumed that whether Sox2 plays an important role in the progression and migration of colon cancer.
Detailed description
In our study, we examined Sox2 expression in archived human colon cancer tissues and found that its Sox2 expression correlates with reduced patient survival, increased tumor grade and metastasis probability.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 24 to 79 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- All rchived 136 tissues were obtained and pathologically confirmed from patients who underwent surgical resections between 2005 and 2006 at the Cancer Center of Sun Yat-sen University (Guangzhou, Guangdong, P. R. China)). The patients from whom the samples were derived underwent curative resection between 2005 and 2006. Tumor differentiation was characterized according to WHO classification, while the surgical pathologic stage was analyzed according to the TNM classification system of the International Union against Cancer. All samples were anonymously coded in accordance with local ethical guidelines.
Key inclusion criteria (1 listed)
- Clinical diagnosis of colorectal cancer
Key exclusion criteria (1 listed)
- Clinical diagnosis characteristics not exactly described in the patients information
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 May 2012.
Related trials for Colorectal Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingObservational study
Pre- and On-treatment Multi-omics Profiling of Locally Advanced Rectal Cancer
Rectal Neoplasms
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 2
Tislelizumab in People With Colorectal Cancer
Colorectal Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Yan Zhang, M.D.Ph.D principal investigator
Laboratory of Cancer and Stem Cell Biology School of Life Sciences Sun Yat-sen University
Questions about this trial
What is this clinical trial studying?
An observational study of Colorectal Cancer, run by Sun Yat-sen University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 May 2012. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 May 2012.